The Role of Gut Microbiome-Derived Short-Chain Fatty Acid Butyrate in Hepatobiliary Diseases
The short-chain fatty acid butyrate, produced from fermentable carbohydrates by gut microbiota in the colon, has multiple beneficial effects on human health. At the intestinal level, butyrate regulates metabolism, helps in the transepithelial transport of fluids, inhibits inflammation, and induces t...
Gespeichert in:
| Veröffentlicht in: | The American journal of pathology 2023-10, Vol.193 (10), p.1455-1467 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1467 |
|---|---|
| container_issue | 10 |
| container_start_page | 1455 |
| container_title | The American journal of pathology |
| container_volume | 193 |
| creator | Pant, Kishor Venugopal, Senthil K. Lorenzo Pisarello, Maria J. Gradilone, Sergio A. |
| description | The short-chain fatty acid butyrate, produced from fermentable carbohydrates by gut microbiota in the colon, has multiple beneficial effects on human health. At the intestinal level, butyrate regulates metabolism, helps in the transepithelial transport of fluids, inhibits inflammation, and induces the epithelial defense barrier. The liver receives a large amount of short-chain fatty acids via the blood flowing from the gut via the portal vein. Butyrate helps prevent nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, inflammation, cancer, and liver injuries. It ameliorates metabolic diseases, including insulin resistance and obesity, and plays a direct role in preventing fatty liver diseases. Butyrate has different mechanisms of action, including strong regulatory effects on the expression of many genes by inhibiting the histone deacetylases and modulating cellular metabolism. The present review highlights the wide range of beneficial therapeutic and unfavorable adverse effects of butyrate, with a high potential for clinically important uses in several liver diseases. |
| doi_str_mv | 10.1016/j.ajpath.2023.06.007 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10548274</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0002944023002389</els_id><sourcerecordid>2835280434</sourcerecordid><originalsourceid>FETCH-LOGICAL-c464t-db4442743981e9894d679fc83f38428bab7ec0a5330a20f87773d4abea6896623</originalsourceid><addsrcrecordid>eNp9kUtv1DAUhS0EotOBf4CQl2yS-hXH2YDK9IVUhARlh2Q5zg3xKBNPbWek-fd4NG3VblhZts-55-h-CH2gpKSEyrN1adZbk4aSEcZLIktC6ldoQStWFYw29DVaEEJY0QhBTtBpjOt8lVyRt-iE14IxKpoF-nM3AP7pR8C-x9dzwt-dDb51fgPFBQS3gw7_GnxIxWowbsJXJqU9Preuw1_ntA8mAc7PN5CrZNvoTNjjCxfBRIjv0JvejBHeP5xL9Pvq8m51U9z-uP62Or8trJAiFV0rhGC14I2i0KhGdLJueqt4z5VgqjVtDZaYinNiGOlVXde8E6YFI1UjJeNL9OU4dzu3G-gsTCmYUW-D2-Q62hunX_5MbtB__U5TUgl1SF6iTw8Tgr-fISa9cdHCOJoJ_Bw1U7xiigh-kIqjNO8pxgD9Uw4l-kBGr_WRjD6Q0UTqTCbbPj7v-GR6RJEFn48CyJvaOQg6WgeThc4FsEl33v0_4R_xKaFD</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2835280434</pqid></control><display><type>article</type><title>The Role of Gut Microbiome-Derived Short-Chain Fatty Acid Butyrate in Hepatobiliary Diseases</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Pant, Kishor ; Venugopal, Senthil K. ; Lorenzo Pisarello, Maria J. ; Gradilone, Sergio A.</creator><creatorcontrib>Pant, Kishor ; Venugopal, Senthil K. ; Lorenzo Pisarello, Maria J. ; Gradilone, Sergio A.</creatorcontrib><description>The short-chain fatty acid butyrate, produced from fermentable carbohydrates by gut microbiota in the colon, has multiple beneficial effects on human health. At the intestinal level, butyrate regulates metabolism, helps in the transepithelial transport of fluids, inhibits inflammation, and induces the epithelial defense barrier. The liver receives a large amount of short-chain fatty acids via the blood flowing from the gut via the portal vein. Butyrate helps prevent nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, inflammation, cancer, and liver injuries. It ameliorates metabolic diseases, including insulin resistance and obesity, and plays a direct role in preventing fatty liver diseases. Butyrate has different mechanisms of action, including strong regulatory effects on the expression of many genes by inhibiting the histone deacetylases and modulating cellular metabolism. The present review highlights the wide range of beneficial therapeutic and unfavorable adverse effects of butyrate, with a high potential for clinically important uses in several liver diseases.</description><identifier>ISSN: 0002-9440</identifier><identifier>ISSN: 1525-2191</identifier><identifier>EISSN: 1525-2191</identifier><identifier>DOI: 10.1016/j.ajpath.2023.06.007</identifier><identifier>PMID: 37422149</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Butyrates - metabolism ; Fatty Acids, Volatile - pharmacology ; Fatty Acids, Volatile - therapeutic use ; Gastrointestinal Microbiome ; Humans ; Inflammation - drug therapy ; Non-alcoholic Fatty Liver Disease - drug therapy ; Review</subject><ispartof>The American journal of pathology, 2023-10, Vol.193 (10), p.1455-1467</ispartof><rights>2023 American Society for Investigative Pathology</rights><rights>Copyright © 2023 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.</rights><rights>2023 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved. 2023 American Society for Investigative Pathology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c464t-db4442743981e9894d679fc83f38428bab7ec0a5330a20f87773d4abea6896623</citedby><cites>FETCH-LOGICAL-c464t-db4442743981e9894d679fc83f38428bab7ec0a5330a20f87773d4abea6896623</cites><orcidid>0000-0002-3505-6616 ; 0000-0003-3222-428X ; 0000-0001-6639-2965 ; 0000-0002-1753-3634</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10548274/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0002944023002389$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,3537,27901,27902,53766,53768,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37422149$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pant, Kishor</creatorcontrib><creatorcontrib>Venugopal, Senthil K.</creatorcontrib><creatorcontrib>Lorenzo Pisarello, Maria J.</creatorcontrib><creatorcontrib>Gradilone, Sergio A.</creatorcontrib><title>The Role of Gut Microbiome-Derived Short-Chain Fatty Acid Butyrate in Hepatobiliary Diseases</title><title>The American journal of pathology</title><addtitle>Am J Pathol</addtitle><description>The short-chain fatty acid butyrate, produced from fermentable carbohydrates by gut microbiota in the colon, has multiple beneficial effects on human health. At the intestinal level, butyrate regulates metabolism, helps in the transepithelial transport of fluids, inhibits inflammation, and induces the epithelial defense barrier. The liver receives a large amount of short-chain fatty acids via the blood flowing from the gut via the portal vein. Butyrate helps prevent nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, inflammation, cancer, and liver injuries. It ameliorates metabolic diseases, including insulin resistance and obesity, and plays a direct role in preventing fatty liver diseases. Butyrate has different mechanisms of action, including strong regulatory effects on the expression of many genes by inhibiting the histone deacetylases and modulating cellular metabolism. The present review highlights the wide range of beneficial therapeutic and unfavorable adverse effects of butyrate, with a high potential for clinically important uses in several liver diseases.</description><subject>Butyrates - metabolism</subject><subject>Fatty Acids, Volatile - pharmacology</subject><subject>Fatty Acids, Volatile - therapeutic use</subject><subject>Gastrointestinal Microbiome</subject><subject>Humans</subject><subject>Inflammation - drug therapy</subject><subject>Non-alcoholic Fatty Liver Disease - drug therapy</subject><subject>Review</subject><issn>0002-9440</issn><issn>1525-2191</issn><issn>1525-2191</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kUtv1DAUhS0EotOBf4CQl2yS-hXH2YDK9IVUhARlh2Q5zg3xKBNPbWek-fd4NG3VblhZts-55-h-CH2gpKSEyrN1adZbk4aSEcZLIktC6ldoQStWFYw29DVaEEJY0QhBTtBpjOt8lVyRt-iE14IxKpoF-nM3AP7pR8C-x9dzwt-dDb51fgPFBQS3gw7_GnxIxWowbsJXJqU9Preuw1_ntA8mAc7PN5CrZNvoTNjjCxfBRIjv0JvejBHeP5xL9Pvq8m51U9z-uP62Or8trJAiFV0rhGC14I2i0KhGdLJueqt4z5VgqjVtDZaYinNiGOlVXde8E6YFI1UjJeNL9OU4dzu3G-gsTCmYUW-D2-Q62hunX_5MbtB__U5TUgl1SF6iTw8Tgr-fISa9cdHCOJoJ_Bw1U7xiigh-kIqjNO8pxgD9Uw4l-kBGr_WRjD6Q0UTqTCbbPj7v-GR6RJEFn48CyJvaOQg6WgeThc4FsEl33v0_4R_xKaFD</recordid><startdate>202310</startdate><enddate>202310</enddate><creator>Pant, Kishor</creator><creator>Venugopal, Senthil K.</creator><creator>Lorenzo Pisarello, Maria J.</creator><creator>Gradilone, Sergio A.</creator><general>Elsevier Inc</general><general>American Society for Investigative Pathology</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-3505-6616</orcidid><orcidid>https://orcid.org/0000-0003-3222-428X</orcidid><orcidid>https://orcid.org/0000-0001-6639-2965</orcidid><orcidid>https://orcid.org/0000-0002-1753-3634</orcidid></search><sort><creationdate>202310</creationdate><title>The Role of Gut Microbiome-Derived Short-Chain Fatty Acid Butyrate in Hepatobiliary Diseases</title><author>Pant, Kishor ; Venugopal, Senthil K. ; Lorenzo Pisarello, Maria J. ; Gradilone, Sergio A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c464t-db4442743981e9894d679fc83f38428bab7ec0a5330a20f87773d4abea6896623</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Butyrates - metabolism</topic><topic>Fatty Acids, Volatile - pharmacology</topic><topic>Fatty Acids, Volatile - therapeutic use</topic><topic>Gastrointestinal Microbiome</topic><topic>Humans</topic><topic>Inflammation - drug therapy</topic><topic>Non-alcoholic Fatty Liver Disease - drug therapy</topic><topic>Review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pant, Kishor</creatorcontrib><creatorcontrib>Venugopal, Senthil K.</creatorcontrib><creatorcontrib>Lorenzo Pisarello, Maria J.</creatorcontrib><creatorcontrib>Gradilone, Sergio A.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The American journal of pathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pant, Kishor</au><au>Venugopal, Senthil K.</au><au>Lorenzo Pisarello, Maria J.</au><au>Gradilone, Sergio A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Role of Gut Microbiome-Derived Short-Chain Fatty Acid Butyrate in Hepatobiliary Diseases</atitle><jtitle>The American journal of pathology</jtitle><addtitle>Am J Pathol</addtitle><date>2023-10</date><risdate>2023</risdate><volume>193</volume><issue>10</issue><spage>1455</spage><epage>1467</epage><pages>1455-1467</pages><issn>0002-9440</issn><issn>1525-2191</issn><eissn>1525-2191</eissn><abstract>The short-chain fatty acid butyrate, produced from fermentable carbohydrates by gut microbiota in the colon, has multiple beneficial effects on human health. At the intestinal level, butyrate regulates metabolism, helps in the transepithelial transport of fluids, inhibits inflammation, and induces the epithelial defense barrier. The liver receives a large amount of short-chain fatty acids via the blood flowing from the gut via the portal vein. Butyrate helps prevent nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, inflammation, cancer, and liver injuries. It ameliorates metabolic diseases, including insulin resistance and obesity, and plays a direct role in preventing fatty liver diseases. Butyrate has different mechanisms of action, including strong regulatory effects on the expression of many genes by inhibiting the histone deacetylases and modulating cellular metabolism. The present review highlights the wide range of beneficial therapeutic and unfavorable adverse effects of butyrate, with a high potential for clinically important uses in several liver diseases.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>37422149</pmid><doi>10.1016/j.ajpath.2023.06.007</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0002-3505-6616</orcidid><orcidid>https://orcid.org/0000-0003-3222-428X</orcidid><orcidid>https://orcid.org/0000-0001-6639-2965</orcidid><orcidid>https://orcid.org/0000-0002-1753-3634</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-9440 |
| ispartof | The American journal of pathology, 2023-10, Vol.193 (10), p.1455-1467 |
| issn | 0002-9440 1525-2191 1525-2191 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10548274 |
| source | MEDLINE; Elsevier ScienceDirect Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Butyrates - metabolism Fatty Acids, Volatile - pharmacology Fatty Acids, Volatile - therapeutic use Gastrointestinal Microbiome Humans Inflammation - drug therapy Non-alcoholic Fatty Liver Disease - drug therapy Review |
| title | The Role of Gut Microbiome-Derived Short-Chain Fatty Acid Butyrate in Hepatobiliary Diseases |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T07%3A59%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Role%20of%20Gut%20Microbiome-Derived%20Short-Chain%20Fatty%20Acid%20Butyrate%20in%20Hepatobiliary%20Diseases&rft.jtitle=The%20American%20journal%20of%20pathology&rft.au=Pant,%20Kishor&rft.date=2023-10&rft.volume=193&rft.issue=10&rft.spage=1455&rft.epage=1467&rft.pages=1455-1467&rft.issn=0002-9440&rft.eissn=1525-2191&rft_id=info:doi/10.1016/j.ajpath.2023.06.007&rft_dat=%3Cproquest_pubme%3E2835280434%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2835280434&rft_id=info:pmid/37422149&rft_els_id=S0002944023002389&rfr_iscdi=true |